01:55 PM EDT, 04/03/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday that it has received a complete response letter from the US Food and Drug Administration and plans to resubmit its new drug application for the potential dry eye disease treatment, reproxalap.

Its shares plunged 72% following an increase in intraday trading volume to more than 18.6 million from a daily average of about 620,000.

Meanwhile, RH (RH) shares sank 38% amid heavy trading after the company reported late Wednesday earnings and sales for fiscal Q4 that missed analysts' expectations.

More than 9.9 million shares traded intraday compared with a daily average of about 796,000.

Additionally, RxSight ( RXST ) said late Wednesday that it lowered its 2025 revenue guidance range to between $160 million and $175 million from its previous projection of $185 million to $197 million.

Following the announcement, shares slumped 38% as intraday trading volume rose to over 3.5 million versus a daily average of about 615,000.

Price: 1.45, Change: -3.88, Percent Change: -72.77